HSBC downgraded Eli Lilly to Reduce in a note released on Tuesday, arguing that investor expectations for the fast-growing obesity drug market have become excessively optimistic and that Lilly's shares are effectively "priced to perfection." The call was led by HSBC analyst Rajesh Kumar and included a reduction in Eli Lilly's price target from $1,070 to $850.
While HSBC said it sees the broader Healthcare sector as positioned to outperform over the coming quarter, the bank cautioned that elevated multiples and crowded positioning within the sector represent a key risk. Against that backdrop, HSBC concluded the risk-reward profile for Lilly is now unfavourable, singling out what it views as inflated assumptions around the obesity market opportunity.
HSBC's three main concerns
- Overstated market size: HSBC wrote that total addressable market expectations for obesity medicines remain elevated - citing market assumptions above USD150 billion - while the bank's own estimate is more conservative, at USD80-120 billion by 2032.
- Rising price pressure: The bank expects price competition to intensify and highlighted that planned price cuts in 2026 will challenge assumptions embedded in Lilly's guidance.
- Oral launch and sales execution risk: HSBC warned that market expectations for Lilly's oral drug launch may be too optimistic. The analysts said that "the compliance and persistence of these drugs might disappoint," and they noted consensus forecasts for 2026 sales appear anchored to a USD1.5 billion inventory build by Lilly.
HSBC also pointed to a divergence between Lilly's guidance and that of Novo Nordisk, attributing part of the difference to Lilly's heavier reliance on the cash-pay channel. The bank suggested that channel may be more sensitive both to the economic cycle and to labour market disruptions tied to AI, increasing the uncertainty around revenue durability.
In addition to the bank's note, the article referenced a third-party AI-driven stock idea product that evaluates LLY along with thousands of other companies using multiple financial metrics. That service highlights stocks by assessing fundamentals, momentum, and valuation, and it cited notable past winners such as Super Micro Computer and AppLovin with substantial historical returns. The referenced product is presented as a tool that scans opportunities across the market.
HSBC's downgrade and the trimmed price target reflect the bank's view that current consensus assumptions for Lilly's obesity-related growth and pricing environment carry significant downside risk if competition, pricing, or patient behaviour diverge from expectations.